Johnson & Johnson: Esophagitis, Peptic trials

The registry lists 10 Esophagitis, Peptic studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 2Phase 3 1Phase 4 3No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• LINX Reflux Management System in Subjects With GERD Who Have Previously Undergone a Laparoscopic Sleeve GastrectomyCompletedNCT02429830Not applicableResults posted
• An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux EsophagitisCompletedNCT01008696Phase 4Results posted
• A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric PatientsCompletedNCT00787891Phase 3Results posted
• A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mgCompletedNCT00464308Phase 4Results posted
• Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease.CompletedNCT01601379
• Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South KoreaCompletedNCT01018160
• A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)CompletedNCT00855361Phase 1
• A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, InclusiveCompletedNCT00747526Phase 1
• Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With RabeprazolTerminatedNCT00511966
• A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)CompletedNCT00216489Phase 4